Trial results for a study (NCT05921760) investigating a combination of Ivosidenib, Nivolumab, and Ipilimumab in previously treated subjects with nonresectable or metastatic IDH1 mutant cholangiocarcinoma were posted on ClinicalTrials.gov on 2026-02-12. This update provides new data for clinicians and researchers exploring therapeutic options for this specific patient population.
Background
The study, identified as NCT05921760, was designed to evaluate the combination of Ivosidenib, Nivolumab, and Ipilimumab. Its primary focus was on individuals who had been previously treated and presented with nonresectable or metastatic IDH1 mutant cholangiocarcinoma.
What this means
The posting of these trial results offers new insights into the potential role of this triple combination therapy for previously treated patients with nonresectable or metastatic IDH1 mutant cholangiocarcinoma. Clinicians and researchers can now access and review the findings from this study, which may inform future research directions and potential therapeutic strategies for patients with this condition.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a comprehensive registry and results database for clinical studies. The results for the study NCT05921760, titled "Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarci," were posted on 2026-02-12.